Neutrophil fates in bronchiectasis and alpha-1 antitrypsin deficiency

Annals of the American Thoracic Society

Volumn 13, Issue , 2016, Pages S123-S129

  Russell, Derek W ^a,c   Gaggar, Amit ^a,b,c,d   Solomon, George M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Bronchiectasis; Cystic fibrosis; Neutrophil; Neutrophil elastase

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; BASOPHIL DEGRANULATION; BRONCHIECTASIS; CELL FATE; CELL MIGRATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; LUNG FIBROSIS; NEUTROPHIL; DISEASE EXACERBATION; IMMUNOLOGY; LUNG;

ALPHA 1-ANTITRYPSIN DEFICIENCY; BRONCHIECTASIS; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; LUNG; NEUTROPHILS;

EID: 84989261668     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201512-805KV     Document Type: Conference Paper

References (76)

1. Albertine KH. Anatomy of the lungs. In: Broaddus VC, Mason RJ, Ernst JE, King TE, Lazarus SC, Murray JF, Nadel JA, Slutsky AS, editors. Murray and Nadel's textbook of respiratory medicine. Philadelphia: Elsevier Saunders; 2016. pp. 3-27.
2. Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Dö ring G. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012;11:363-382.
3. Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol 2014;15:602-611.
4. Howard TH, Watts RG. Actin polymerization and leukocyte function. Curr Opin Hematol 1994;1:61-68.
5. Liu L, Mul FP, Kuijpers TW, Lutter R, Roos D, Knol EF. Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cells is regulated by different mechanisms. Ann N Y Acad Sci 1996;796:21-29.
6. 1-antitrypsin deficiency. J Clin Invest 1999;104:337-344.
7. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51.
8. Mayer-Scholl A, Averhoff P, Zychlinsky A. How do neutrophils and pathogens interact? Curr Opin Microbiol 2004;7:62-66.
9. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535.
10. Houston N, Stewart N, Smith DS, Bell SC, Champion AC, Reid DW. Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. J Cyst Fibros 2013;12:352-362.
11. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13:1423-1430.
12. Le-Barillec K, Si-Tahar M, Balloy V, Chignard M. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J Clin Invest 1999;103:1039-1046.
13. Tosi MF, Zakem H. Surface expression of Fc g receptor III (CD16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments. J Clin Invest 1992;90:462-470.
14. Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci USA 2008;105:4335-4339.
15. Gaggar A, Li Y, Weathington N, Winkler M, Kong M, Jackson P, Blalock JE, Clancy JP. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 2007;293:L96-L104.
16. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, Clancy JP, Blalock JE. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180:5662-5669.
17. ClinicalTrials.gov. Trial of doxycycline to reduce sputum MMP-9 activity in adult cystic fibrosis (CF) patients (DOXY) [updated 2013 Dec. 19; accessed 2016 Jan 4]. Available from: https://clinicaltrials. gov/ct2/show/NCT01112059
18. Laval J, Touhami J, Herzenberg LA, Conrad C, Taylor N, Battini JL, Sitbon M, Tirouvanziam R. Metabolic adaptation of neutrophils in cystic fibrosis airways involves distinct shifts in nutrient transporter expression. J Immunol 2013;190:6043-6050.
19. Morris MR, Doull IJ, Dewitt S, Hallett MB. Reduced iC3b-mediated phagocytotic capacity of pulmonary neutrophils in cystic fibrosis. Clin Exp Immunol 2005;142:68-75.
20. Mitchell T, Lo A, Logan MR, Lacy P, Eitzen G. Primary granule exocytosis in human neutrophils is regulated by Rac-dependent actin remodeling. Am J Physiol Cell Physiol 2008;295:C1354-C1365.
21. Pohl K, Hayes E, Keenan J, Henry M, Meleady P, Molloy K, Jundi B, Bergin DA, McCarthy C, McElvaney OJ, et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 2014;124:999-1009.
22. Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros 2016;15:67-73.
23. Manzenreiter R, Kienberger F, Marcos V, Schilcher K, KrautgartnerWD, Obermayer A, Huml M, Stoiber W, Hector A, Griese M, et al. Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. J Cyst Fibros 2012;11:84-92.
24. Cheng OZ, Palaniyar N. NET balancing: a problem in inflammatory lung diseases. Front Immunol 2013;4:1.
25. Rada B, Jendrysik MA, Pang L, Hayes CP, Yoo DG, Park JJ, Moskowitz SM, Malech HL, Leto TL. Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS One 2013;8:e54205.
26. Douda DN, Grasemann H, Pace-Asciak C, Palaniyar N. A lipid mediator hepoxilin A3 is a natural inducer of neutrophil extracellular traps in human neutrophils. Mediators Inflamm 2015;2015:520871.
27. Dwyer M, Shan Q, D'Ortona S, Maurer R, Mitchell R, Olesen H, Thiel S, Huebner J, Gadjeva M. Cystic fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular trap release is regulated by macrophage migration-inhibitory factor. J Innate Immun 2014;6:765-779.
28. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, et al. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One 2011;6:e23637.
29. Rahman S, Gadjeva M. Does NETosis contribute to the bacterial pathoadaptation in cystic fibrosis? Front Immunol 2014;5:378.
30. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188:647-656.
31. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-439.
32. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-1284.
33. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
34. Eller J, Lapa e Silva JR, Poulter LW, Lode H, Cole PJ. Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci 1994;725:331-345.
35. Angrill J, Agust C, de Celis R, Rañó A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57:15-19.
36. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55:27-34.
37. Watt AP, Brown V, Courtney J, Kelly M, Garske L, Elborn JS, Ennis M. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004;59:231-236.
38. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, Kay AB, Durham SR. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998;53:685-691.
39. Mikami M, Llewellyn-Jones CG, Bayley D, Hill SL, Stockley RA. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998;157:723-728.
40. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31:396-406.
41. Stockley RA, Bayley DL. Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000;15:778-781.
42. Chalmers JD, Finch S. Sputum colour in non-CF bronchiectasis: the original neutrophil biomarker. Respirology 2014;19:153-154.
43. Schaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J. Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration 2000;67:52-59.
44. Russell KJ, McRedmond J, Mukherji N, Costello C, Keatings V, Linnane S, Henry M, Fitzgerald MX, O'Connor CM. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. Am J Respir Crit Care Med 1998;157:756-761.
45. Karakoc GB, Inal A, Yilmaz M, Altintas DU, Kendirli SG. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol 2009;44:1010-1016.
46. Voglis S, Quinn K, Tullis E, Liu M, Henriques M, Zubrinich C, Peñuelas O, Chan H, Silverman F, Cherepanov V, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009;180:159-166.
47. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84:1302-1313.
48. King P, Bennett-Wood V, Hutchinson P, Robins-Browne R, Holmes P, Freezer N, Holdsworth S. Bactericidal activity of neutrophils with reduced oxidative burst from adults with bronchiectasis. APMIS 2009;117:133-139.
49. Hirche TO, Benabid R, Deslee G, Gangloff S, Achilefu S, Guenounou M, Lebargy F, Hancock RE, Belaaouaj A. Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa. J Immunol 2008;181:4945-4954.
50. Hazeldine J, Harris P, Chapple IL, Grant M, Greenwood H, Livesey A, Sapey E, Lord JM. Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. Aging Cell 2014;13:690-698.
51. 1-Antitrypsin review. Clin Chest Med 2014;35:39-50.
52. Stockley RA. The multiple facets of alpha-1-antitrypsin. Ann Transl Med 2015;3:130.
53. 4by alveolar macrophages. J Clin Invest 1991;88:891-897.
54. 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond) 1987;72:373-381.
55. 1-antitrypsin deficiency. Eur Respir J 2012;40:561-569.
56. 1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 2004;286:L514-L520.
57. 1-antitrypsin deficiency. Eur Respir J 2000;15:886-890.
58. 1-antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002;57:709-714.
59. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-1484.
60. Lee KH, Lee CH, Jeong J, Jang AH, Yoo CG. Neutrophil elastase differentially regulates interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF) production by cigarette smoke extract. J Biol Chem 2015;290:28438-28445.
61. 1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol Med 2011;17:865-874.
62. Djekic UV, Gaggar A, Weathington NM. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009;121:132-146.
63. Wells JM, Gaggar A, Blalock JE. MMP generated matrikines. Matrix Biol 2015;44-46:122-129.
64. 1-antitrypsin deficiency. Proc Am Thorac Soc 2010;7:381-386.
65. 1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166:377-386.
66. Khan AJ, Evans HE, Agbayani MM. Defective neutrophil chemotaxis in patients with alpha-1-antitrypsin deficiency. Eur J Pediatr 1986;144:464-466.
67. Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, Condron C, Chotirmall SH, Clynes M, O'Neill SJ, et al. a-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120:4236-4250.
68. Lomas DA, Stone SR, Llewellyn-Jones C, Keogan MT, Wang ZM, Rubin H, Carrell RW, Stockley RA. The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin. J Biol Chem 1995;270:23437-23443.
69. 1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci USA 2013;110:15007-15012.
70. 1-antitrypsin therapy. Mol Med 2012;18:957-970.
71. Hurley K, Lacey N, O'Dwyer CA, Bergin DA, McElvaney OJ, O'Brien ME, McElvaney OF, Reeves EP, McElvaney NG. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals. J Immunol 2014;193:3978-3991.
72. 1-.
73. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002;1:19-25.
74. Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 2003;31(4, Suppl):S189-S194.
75. Pott GB, Beard KS, Bryan CL, Merrick DT, Shapiro L. Alpha-1 antitrypsin reduces severity of Pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and Pseudomonas invasion of respiratory epithelial cells. Front Public Health 2013;1:19.
76. 1-Antitrypsin inhibits the activity of the matriptase catalytic domain in vitro. Am J Respir Cell Mol Biol 2008;39:631-637.